Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin vs alfuzosin vs placebo crossover study of retrograde ejaculation in men with lower urinary tract symptoms
ACTRN12625000738426Phase 4Not yet recruiting
- Sponsor
- Toowoomba Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of silodosin and alfuzosin in Micturition disorder and benign prostatic hyperplasia (BPH) (6 arms), sponsored by Toowoomba Hospital. Primary endpoint: Semen analysis composite for retrograde ejaculation. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
silodosinalfuzosin
03
Conditions
Micturition disorderbenign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ACTRN12625000738426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000738426.